

# Jidong Jia

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4633140/jidong-jia-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140  
papers

3,107  
citations

24  
h-index

52  
g-index

160  
ext. papers

4,293  
ext. citations

6.2  
avg, IF

4.97  
L-index

#	Paper	IF	Citations
140	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , <b>2017</b> , 11, 317-370	8.8	955
139	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 700-710	13.4	236
138	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). <i>Journal of Clinical and Translational Hepatology</i> , <b>2017</b> , 5, 297-318	5.2	136
137	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. <i>Gut</i> , <b>2016</b> , 65, 313-20	19.2	85
136	Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. <i>Hepatology International</i> , <b>2017</b> , 11, 461-471	8.8	81
135	New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. <i>Hepatology</i> , <b>2017</b> , 65, 1438-1450	11.2	75
134	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. <i>Hepatology</i> , <b>2014</b> , 59, 1283-92	11.2	62
133	Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 756-62		57
132	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 776-787	18.8	51
131	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 52-62	18.8	43
130	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1368-1378	13.4	41
129	Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia. <i>Hepatology International</i> , <b>2016</b> , 10, 854-860	8.8	38
128	ECM1 Prevents Activation of Transforming Growth Factor $\beta$ Hepatic Stellate Cells, and Fibrogenesis in Mice. <i>Gastroenterology</i> , <b>2019</b> , 157, 1352-1367.e13	13.3	35
127	Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis. <i>Hepatology</i> , <b>2020</b> , 72, 729-741	11.2	35
126	Systemic inflammatory response syndrome in acute-on-chronic liver failure: Relevance of Golden windowRA prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1989-1997		31
125	Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 16498-16506	3.3	31
124	Autoimmune hepatitis: East meets west. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1230-6	4	30

123	Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2018</b> , 1864, 1129-1137	6.9	28
122	A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1860-1867	4	28
121	Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1929-1936.e1	6.9	28
120	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 674-682	13.4	27
119	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2018</b> , 54, 282-294	12.3	26
118	Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 929-937	0.7	25
117	Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. <i>Hepatology International</i> , <b>2019</b> , 13, 91-101	8.8	24
116	On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis. <i>Liver International</i> , <b>2018</b> , 38, 1045-1054	7.9	23
115	Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2582-2591.e6	6.9	22
114	Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. <i>Modern Pathology</i> , <b>2018</b> , 31, 1191-1200	9.8	22
113	The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 454-461	13.4	22
112	Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 748-55	4	21
111	An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma. <i>EBioMedicine</i> , <b>2015</b> , 2, 438-46	8.8	20
110	How to control highly endemic hepatitis B in Asia. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 122-125	7.9	19
109	Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. <i>Hepatology International</i> , <b>2020</b> , 14, 105-114	8.8	19
108	Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. <i>Hepatology International</i> , <b>2019</b> , 13, 788-799	8.8	18
107	Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. <i>Hepatology International</i> , <b>2019</b> , 13, 766-776	8.8	17
106	Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1676-1684	4	17

105	Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice. <i>International Journal of Molecular Medicine</i> , <b>2017</b> , 40, 454-464	4.4	17
104	Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 12-21	4	17
103	Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy. <i>Scientific Reports</i> , <b>2018</b> , 8, 2989	4.9	16
102	Exosomal microRNA in autoimmunity. <i>Cellular and Molecular Immunology</i> , <b>2019</b> , 16, 932-934	15.4	16
101	Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144425	3.7	16
100	Non- mutations in haemochromatosis in China: combination of heterozygous mutations involving signal peptide variants. <i>Journal of Medical Genetics</i> , <b>2018</b> , 55, 650-660	5.8	16
99	Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. <i>Hepatology International</i> , <b>2018</b> , 12, 126-132	8.8	15
98	Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 839-849	18.8	15
97	A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. <i>Medicine (United States)</i> , <b>2016</b> , 95, e5391	1.8	15
96	Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 576-585	3.4	15
95	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. <i>Hepatology Research</i> , <b>2018</b> , 48, E213-E221	5.1	14
94	Matrix metalloproteinase-1 induction by diethyldithiocarbamate is regulated via Akt and ERK/miR222/ETS-1 pathways in hepatic stellate cells. <i>Bioscience Reports</i> , <b>2016</b> , 36,	4.1	14
93	Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. <i>Hepatology</i> , <b>2020</b> , 71, 463-476	11.2	14
92	Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B. <i>Hepatology International</i> , <b>2018</b> , 12, 118-125	8.8	13
91	Inorganic nitrate alleviates the senescence-related decline in liver function. <i>Science China Life Sciences</i> , <b>2018</b> , 61, 24-34	8.5	13
90	Clinicopathological features of He Shou Wu-induced liver injury: This ancient anti-aging therapy is not liver-friendly. <i>Liver International</i> , <b>2019</b> , 39, 389-400	7.9	13
89	Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. <i>Scientific Reports</i> , <b>2015</b> , 5, 17123	4.9	13
88	OX40 Regulates Both Innate and Adaptive Immunity and Promotes Nonalcoholic Steatohepatitis. <i>Cell Reports</i> , <b>2018</b> , 25, 3786-3799.e4	10.6	13

87	Platelets increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis. <i>Hepatology International</i> , <b>2018</b> , 12, 237-243	8.8	12
86	Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 61-69	5.4	12
85	Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2018</b> , 110, 557-563	0.9	12
84	Dynamics of elastin in liver fibrosis: Accumulates late during progression and degrades slowly in regression. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 22613-22622	7	11
83	Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy. <i>Hepatology Research</i> , <b>2018</b> , 48, E283-E290	5.1	11
82	Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. <i>British Journal of Pharmacology</i> , <b>2018</b> , 175, 4480-4495	8.6	11
81	A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. <i>Value in Health Regional Issues</i> , <b>2013</b> , 2, 48-56	1.6	10
80	A brief review on prognostic models of primary biliary cholangitis. <i>Hepatology International</i> , <b>2017</b> , 11, 412-418	8.8	10
79	Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2499-2513	6.9	10
78	Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. <i>Scientific Reports</i> , <b>2016</b> , 6, 37498	4.9	10
77	Chronic HBV: which pregnant women should be treated?. <i>Liver International</i> , <b>2016</b> , 36 Suppl 1, 105-8	7.9	10
76	Tanshinone IIA promotes the proliferation of WB-F344 hepatic oval cells via Wnt/ $\beta$ -catenin signaling. <i>Molecular Medicine Reports</i> , <b>2016</b> , 13, 1501-8	2.9	9
75	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. <i>Hepatology International</i> , <b>2014</b> , 8, 382-94	8.8	9
74	Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 213-220	5.2	9
73	Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients. <i>Modern Pathology</i> , <b>2018</b> , 31, 1567-1577	9.8	9
72	Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. <i>Infection and Drug Resistance</i> , <b>2019</b> , 12, 745-757	4.2	8
71	Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. <i>Gastroenterology Research and Practice</i> , <b>2019</b> , 2019, 8959103	2	8
70	Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 221-225	5.2	8

69	Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities. <i>JHEP Reports</i> , <b>2020</b> , 2, 100165	10.3	8
68	A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China. <i>Liver International</i> , <b>2019</b> , 39, 1120-1127	7.9	8
67	Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 201-209 <sup>1.6</sup>		7
66	Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1236-1241	4	7
65	Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 196-204.e8 <sup>6.9</sup>		7
64	Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 1423-1434	4	7
63	Mutation analysis of the gene in Chinese patients with Dubin-Johnson syndrome. <i>Experimental and Therapeutic Medicine</i> , <b>2018</b> , 16, 4201-4206	2.1	7
62	FoxA2 inhibits the proliferation of hepatic progenitor cells by reducing PI3K/Akt/HK2-mediated glycolysis. <i>Journal of Cellular Physiology</i> , <b>2020</b> , 235, 9524-9537	7	6
61	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , <b>2020</b> , 5, 1129-1138	4.1	6
60	Anti-HBc-positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2014</b> , 38, 475-80	2.4	6
59	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1540-1550	6.1	6
58	Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice. <i>Hepatology International</i> , <b>2021</b> , 15, 1122-1135 <sup>8.8</sup>		6
57	A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B. <i>International Journal of Environmental Research and Public Health</i> , <b>2016</b> , 13,	4.6	6
56	Complex ATP7B mutation patterns in Wilson disease and evaluation of a yeast model for functional analysis of variants. <i>Human Mutation</i> , <b>2019</b> , 40, 552-565	4.7	5
55	Functional restoration of CD56 NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B. <i>Hepatology International</i> , <b>2017</b> , 11, 419-428	8.8	5
54	Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. <i>Journal of Digestive Diseases</i> , <b>2020</b> , 21, 519-525	3.3	5
53	The Characteristics Variation of Hepatic Progenitors after TGF- $\beta$ -Induced Transition and EGF-Induced Reversion. <i>Stem Cells International</i> , <b>2016</b> , 2016, 6304385	5	5
52	A High Serum Level of Taurocholic Acid Is Correlated With the Severity and Resolution of Drug-induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1009-1019.e11	6.9	5

51	Correlation of genotype and phenotype in 32 patients with hereditary hemochromatosis in China. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 398	4.2	5
50	HFE-Related Hemochromatosis in a Chinese Patient: The First Reported Case. <i>Frontiers in Genetics</i> , <b>2020</b> , 11, 77	4.5	4
49	Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cut-off to assess fibrosis stages. <i>Journal of Digestive Diseases</i> , <b>2020</b> , 21, 279-286	3.3	4
48	Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. <i>International Journal of Infectious Diseases</i> , <b>2018</b> , 67, 58-64	10.5	4
47	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199198	3.7	4
46	Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. <i>Journal of Digestive Diseases</i> , <b>2019</b> , 20, 467-475	3.3	3
45	SHG/TPEF-based image technology improves liver fibrosis assessment of minimally sized needle biopsies. <i>Hepatology International</i> , <b>2019</b> , 13, 501-509	8.8	3
44	A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFN $\alpha$ therapy in Chinese HBeAg-positive chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 469-478	6.1	3
43	Inhibitory effects of HNF4 $\beta$ on migration/maltransformation of hepatic progenitors: HNF4 $\beta$ overexpressing hepatic progenitors for liver repopulation. <i>Stem Cell Research and Therapy</i> , <b>2017</b> , 8, 183	8.3	3
42	A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 249-257	5.2	3
41	Prolonged interval of total bilirubin decline is an early independent predictive factor of chronic persistent drug-induced liver injury. <i>Hepatology Research</i> , <b>2020</b> , 50, 224-232	5.1	3
40	Screening varices in patients with HBV-related cirrhosis on antiviral therapy: Platelet alone or together with LSM. <i>Liver International</i> , <b>2021</b> , 41, 369-377	7.9	3
39	Therapeutic vaccine BR11-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. <i>JHEP Reports</i> , <b>2021</b> , 3, 100361	10.3	3
38	Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. <i>The Lancet Regional Health - Western Pacific</i> , <b>2021</b> , 16, 100249	5	3
37	Mesenchymal stem cells protect against acetaminophen hepatotoxicity by secreting regenerative cytokine hepatocyte growth factor.. <i>Stem Cell Research and Therapy</i> , <b>2022</b> , 13, 94	8.3	3
36	Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. <i>JAMA Oncology</i> , <b>2019</b> , 5, 915-916	13.4	2
35	On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon $\alpha$ add-on therapy. <i>Journal of Medical Virology</i> , <b>2019</b> , 91, 1499-1509	19.7	2
34	A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China. <i>Orphanet Journal of Rare Diseases</i> , <b>2020</b> , 15, 74	4.2	2

33	EGF neutralization antibodies attenuate liver fibrosis by inhibiting myofibroblast proliferation in bile duct ligation mice. <i>Histochemistry and Cell Biology</i> , <b>2020</b> , 154, 107-116	2.4	2
32	Critical role of OX40 in drug-induced acute liver injury. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 3183-3196	3.1	2
31	Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections. <i>BMJ Open Gastroenterology</i> , <b>2014</b> , 1, e000010	3.9	2
30	Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 322-328	5.2	2
29	Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 391	3	2
28	China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. <i>Scandinavian Journal of Public Health</i> , <b>2020</b> , 48, 233-239	3	2
27	Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 2375-2382	4	2
26	Nondegradable Collagen Increases Liver Fibrosis but Not Hepatocellular Carcinoma in Mice. <i>American Journal of Pathology</i> , <b>2021</b> , 191, 1564-1579	5.8	2
25	A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. <i>OMICS A Journal of Integrative Biology</i> , <b>2020</b> , 24, 415-423	3.8	1
24	Irradiated and CCl <sub>4</sub> -treated bone marrow-derived liver macrophages exhibit different gene expression patterns and phenotypes. <i>Scandinavian Journal of Immunology</i> , <b>2020</b> , 92, e12916	3.4	1
23	Incorrect calculation and inappropriate interpretation: accuracy of international guidelines for identifying significant fibrosis in e antigen-negative chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1407-9	6.9	1
22	The Role of Fibrocytes in Fibrogenic Liver Diseases. <i>Current Pathobiology Reports</i> , <b>2014</b> , 2, 191-199	2	1
21	Consensus on the secondary prevention of primary liver cancer. <i>Hepatology International</i> , <b>2021</b> , 15, 1289-1300	13.00	1
20	Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study. <i>Antiviral Therapy</i> , <b>2020</b> , 25, 293-304	1.6	1
19	Control of Chronic Hepatitis B in China: Perspective of Diagnosis and Treatment. <i>China CDC Weekly</i> , <b>2020</b> , 2, 596-600	4	1
18	Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 329-338	6.1	1
17	Prevention of Mother-to-Child Transmission of Hepatitis B Virus in the Western Pacific Region. <i>Clinical Liver Disease</i> , <b>2021</b> , 18, 18-21	2.2	1
16	Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	1



15	Impact of the Kasai Procedure and the Length of Native Liver Survival Time on Outcomes of Liver Transplantation for Biliary Atresia. <i>Liver Transplantation</i> , <b>2021</b> ,	4.5	1
14	Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis.. <i>Hepatology International</i> , <b>2022</b> , 16, 195	8.8	o
13	Clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis induced by Leishmania infantum infection. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009944	4.8	o
12	Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis. <i>Hepatology International</i> , <b>2021</b> , 15, 1318-1327	8.8	o
11	Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. <i>Hepatology International</i> , <b>2021</b> , 15, 611-620	8.8	o
10	Role of tight junction-associated MARVEL protein marvelD3 in migration and epithelial-mesenchymal transition of hepatocellular carcinoma. <i>Cell Adhesion and Migration</i> , <b>2021</b> , 15, 249-260	3.2	o
9	Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy. <i>Hepatology International</i> , <b>2021</b> , 15, 82-92	8.8	o
8	Non-invasive evaluation of esophageal varices in patients with liver cirrhosis using low-dose splenic perfusion CT.. <i>European Journal of Radiology</i> , <b>2022</b> , 152, 110326	4.7	o
7	Enhanced Performance of Proliferation Assay of Bone Marrow Cells by Optimizing in vivo Incorporation of 5-Ethynyl-2'-Deoxyuridine and Cell Preparation for Flow Cytometry. <i>Analytical Letters</i> , <b>2016</b> , 49, 2132-2145	2.2	
6	A multimodal international collaborative clinical research training program in China. <i>Medical Education Online</i> , <b>2019</b> , 24, 1679944	4.4	
5	Reply:. <i>Hepatology</i> , <b>2008</b> , 47, 1425-1426	11.2	
4	Advances in the diagnosis and treatment of viral hepatitis B and C in China.. <i>Chinese Medical Journal</i> , <b>2021</b> , 135, 379-380	2.9	
3	Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. <i>Journal of Clinical and Translational Hepatology</i> , <b>2020</b> , 8, 255-261	5.2	
2	GITR/GITRL reverse signalling modulates the proliferation of hepatic progenitor cells by recruiting ANXA2 to phosphorylate ERK1/2 and Akt.. <i>Cell Death and Disease</i> , <b>2022</b> , 13, 297	9.8	
1	Adult-onset Type II Citrullinemia manifested as steatosis or steatohepatitis: a report of three Chinese cases.. <i>Journal of Digestive Diseases</i> , <b>2022</b> ,	3.3	